Published -July 17th, 2023 @ 2:50 PM (GMT+2 )

‍

As the landscape of the global economy continues to evolve, understanding the latest financial updates is more important than ever. Navigating the complex world of finance can be overwhelming, but keeping up-to-date with the significant market movements can empower investors and businesses to make informed decisions. In the following article, we delve into the top 5 vital financial trends and events that have the potential to shape the markets in the upcoming week. From stock market performances to executive moves, we've covered you with the essential news you need to know.

‍

‍

1. BridgeBio Pharma: Potential Breakthrough on the Horizon - Stock Soars

‍

With BridgeBio Pharma set to announce results from the phase 3 ATTRibute-CM clinical trial for its oral drug, acoramidis, investors are on edge. The trial is investigating a treatment for a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM).

As the company estimates a $15 billion annual market opportunity, the successful trial outcome could trigger a surge in BridgeBio's share price, which has already seen a nearly 15% increase in after-hours trading on Friday. If successful, acoramidis could achieve blockbuster status, potentially generating over $1 billion a year in sales.

Currently, BridgeBio Pharma's stock (NASDAQ:BBIO) is valued at $18.22, up 10.29% since June 20, and has soared 154.11% year-to-date, signaling a bullish sentiment among investors.

The company, valued at $2.92 billion, specializes in developing treatments for genetic diseases.
‍

‍

2. Pfizer's $43B Seagen Acquisition Under EU and FTC Scrutiny

‍

Pfizer's proposed $43 billion takeover of Seagen is under investigation by the European Union and the US Federal Trade Commission (FTC). The deal, announced in March, would bolster Pfizer's early-stage experimental cancer therapies portfolio by incorporating Seagen's leading antibody-drug conjugates. However, EU approval is now a requirement for the deal to proceed.

The FTC has also made a second request for additional details, a measure that only occurs in roughly 25% of large deals and results in court challenges about 5-10% of the time. Despite the scrutiny, Seagen and Pfizer maintain their expectation of closing the deal in late 2023 or early 2024.

Currently, Pfizer's (NYSE:PFE) shares are valued at $36.32, marking a YTD drop of 29.15%, while Seagen (NASDAQ:SGEN) stands at $198.00 per share, up 53.85% YTD.

‍
‍
3. Tesla Unveils First Cybertruck Amid Earnings and Margin Queries

‍

After two years of delays, Tesla has finally produced its first Cybertruck, with mass production slated for year-end. The electric vehicle maker's CEO, Elon Musk, anticipates manufacturing between 250,000 to 500,000 units per year, subject to demand.

The Cybertruck's launch puts Tesla in direct competition with Ford and Rivian in the profitable EV pickup segment. However, investor focus remains on Tesla's forthcoming Q2 earnings report and concerns over its non-GAAP auto gross margins.

Tesla's stock (NASDAQ:TSLA), which has risen by 160.30% YTD, currently trades at $281.38. Analysts will be closely following Wednesday's Q2 earnings call for firm details on the Cybertruck's production, delivery, and specifications.
‍

4. Sony Ensures Call of Duty's Presence on PlayStation with a Decade-Long Deal

‍

Sony has sealed a 10-year contract with Microsoft for the Call of Duty franchise, affirming the game's future on PlayStation post Microsoft's acquisition of Activision Blizzard. The groundbreaking agreement ends a year-long negotiation and quashes fears of Microsoft monopolizing the franchise for Xbox.

The deal also deflates opposition from PlayStation Chief, Jim Ryan, to the merger and a new Call of Duty contract. Microsoft's shares (NASDAQ:MSFT) have seen a year-to-date (YTD) increase of 44.10%, currently trading at $345.24.

In contrast, Sony's stock (NYSE:SONY) witnessed a YTD growth of 20.53% and trades at $92.39. Amid these developments, Activision (NASDAQ:ATVI) has experienced a 9.99% surge since June 20, 2023, now priced at $90.07.

The unfolding dynamics between these tech titans will continue to shape the digital gaming landscape.

‍

5. GM's Roll of the Dice: Ditching Apple CarPlay for Google Infotainment Sparks Dealer Concerns

‍

General Motors' (GM) bold decision to phase out Apple's (NASDAQ:AAPL) CarPlay in favor of a new integrated infotainment system has sparked alarm among its dealers.

GM's future electric vehicles (EVs) will feature Google's (NASDAQ:GOOGL) built-in applications and other apps such as Spotify (NYSE:SPOT) and Audible (NASDAQ:AMZN), starting with the 2024 Chevy Blazer EV.

The transition raises eyebrows, considering CarPlay's popularity among 79% of new car buyers. Despite GM's optimism about its partnership with Google, industry analyst Karl Brauer warns that this revenue-driven move could backfire.

GM's shares (NYSE:GM) trade at $40.00, with a 7.18% increase since June 20, 2023.

As the company forges ahead with its data-focused strategy, the industry awaits the consumer response to GM's new in-car technology.

‍

Conclusion
‍
In conclusion, the pharmaceutical, automotive, gaming, and tech industries are witnessing significant changes and possible breakthroughs.
BridgeBio Pharma's potentially successful ATTR-CM clinical trial could cause its share price to soar, while Pfizer's proposed acquisition of Seagen faces regulatory scrutiny.
Tesla's unveiling of the first Cybertruck, despite margin concerns, puts it in direct competition in the profitable EV pickup segment.
In the gaming sector, Sony's decade-long deal with Microsoft ensures Call of Duty's presence on PlayStation, even amidst industry consolidation.
Finally, GM's bold decision to phase out Apple's CarPlay for a Google-based infotainment system could reshape in-car entertainment but also raises concerns among dealers.
These developments underscore the dynamic nature of these industries and their potential for unexpected disruption and innovation.

‍

The information on mexem.com is for general informational purposes only. It should not be regarded as investment advice. Investing in stocks involves risk. A stock's past performance is not a reliable indicator of its future performance. Always consult a financial advisor or trusted sources before making any investment decisions.

‍